Furthermore, practical molecular classification of endometrial cancer utilizing MMR IHC or MLH1 promotor methylation test ± p53 IHC would not only help in screening Lynch syndrome, but also to predict the prognosis of endometrial cancer patients; this in turn would aid in determining the extent of surgery and adjuvant therapeutic modality, including targeted therapy. Here, TP53 is linked to Lynch syndrome.